Cargando…
Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients
BACKGROUND: Effective therapies to combat coronavirus 2019 (COVID-19) are urgently needed. Hydroxychloroquine (HCQ) has in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the clinical benefit of HCQ in treating COVID-19 is unclear. Randomized contro...
Autores principales: | Ulrich, Robert J, Troxel, Andrea B, Carmody, Ellie, Eapen, Jaishvi, Bäcker, Martin, DeHovitz, Jack A, Prasad, Prithiv J, Li, Yi, Delgado, Camila, Jrada, Morris, Robbins, Gabriel A, Henderson, Brooklyn, Hrycko, Alexander, Delpachitra, Dinuli, Raabe, Vanessa, Austrian, Jonathan S, Dubrovskaya, Yanina, Mulligan, Mark J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543602/ https://www.ncbi.nlm.nih.gov/pubmed/33134417 http://dx.doi.org/10.1093/ofid/ofaa446 |
Ejemplares similares
-
27. Co-infections and antimicrobial use in patients hospitalized with COVID-19
por: Prasad, Prithiv, et al.
Publicado: (2021) -
Coinfections and antimicrobial use in patients hospitalized with coronavirus disease 2019 (COVID-19) across a single healthcare system in New York City: A retrospective cohort study
por: Prasad, Prithiv J., et al.
Publicado: (2022) -
Outcomes of Cytomegalovirus Viremia Treatment in Critically Ill Patients With COVID-19 Infection
por: Schoninger, Scott, et al.
Publicado: (2022) -
Clinical Outcomes of Ceftriaxone vs Penicillin G for Complicated Viridans Group Streptococci Bacteremia
por: Wo, Stephanie, et al.
Publicado: (2020) -
Carbapenem-Resistant Enterobacteriaceae Infections in Patients on Renal Replacement Therapy
por: Eilertson, Brandon, et al.
Publicado: (2017)